DIVISLAB · Healthcare
The board meets on 7 Nov 2026 to approve the results. This page fills in when the numbers are filed.
| Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,909 cr | ₹1,855 cr | ₹2,303 cr | ₹2,118 cr | ₹2,338 cr | ₹2,319 cr | ₹2,585 cr | ₹2,410 cr | ₹2,715 cr | ₹2,604 cr | ₹2,831 cr | ₹3,080 cr |
| YoY | — | — | — | +19% | +22% | +25% | +12% | +14% | +16% | +12% | +10% | +28% |
| EBITDA margin | 25.1% | 26.4% | 31.7% | 29.4% | 30.6% | 32.0% | 34.3% | 30.2% | 32.7% | 34.2% | 33.0% | 40.7% |
| Other income, % of PBT | 18% | 19% | 11% | 13% | 15% | 11% | 10% | 16% | 16% | 2% | 16% | 5% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 26% | 27% | 25% | 29% | 29% | 19% | 23% | 26% | 24% | 25% | 22% | 24% |
| Net profit | ₹348 cr | ₹358 cr | ₹538 cr | ₹430 cr | ₹510 cr | ₹589 cr | ₹662 cr | ₹545 cr | ₹689 cr | ₹583 cr | ₹751 cr | ₹902 cr |
| YoY | — | — | — | +21% | +47% | +65% | +23% | +27% | +35% | −1% | +13% | +66% |
| Core profit YoY | — | — | — | +28% | +61% | +63% | +23% | +17% | +25% | +19% | +4% | +82% |
| EPS | ₹13.11 | ₹13.49 | ₹20.27 | ₹16.20 | ₹19.21 | ₹22.19 | ₹24.94 | ₹20.53 | ₹25.95 | ₹21.96 | ₹28.29 | ₹33.98 |
| Flags | · | · | · | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.